For Children Two-Years of Age and Younger
The Jazz Piccolo Study (Piccolo means “little one” in Italian) is investigating the safety and effectiveness of cannabidiol (or CBD oral solution) in infants (2 years of age and younger) with Tuberous Sclerosis Complex (TSC), Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) who experience inadequately controlled seizures.
TSC, LGS and DS are rare, early-onset epilepsies with life-long impact. Current treatment options for seizures associated with these conditions have substantial limitations, including poor seizure control and numerous side effects. Studies have shown that poor seizure control leads to additional health issues and a lower quality of life for those affected. Therefore, early treatment and control of seizures may be critical in improving the outcomes for children with these conditions.
Study Sites in the United States:
- Cincinnati Children’s Hospital Medical Center
- Arkansas Children’s Hospital
- Baylor College of Medicine/Texas Children’s Hospital
For more information about the Jazz Piccolo Study visit jazzpiccolostudy.com
Additional Information:
View the Jazz Piccolo Study Brochure 
Visit the Jazz Piccolo Study Website
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.
Updated 04/04/2024